Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imetelstat in lower-risk myelodysplastic syndrome
RBR-9jqhycPhase 3Recruiting
- Sponsor
- Hospital de Amor
- Start
- Feb 2015
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing Imetelstat with Placebo (2 arms). Started Feb 2015; status: recruiting.
02
Drugs
imetelstat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on RBR-9jqhyc.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-9jqhyc.